SCHEMBL3383582

SCHEMBL3383582

COc1ccc(-c2cnc(Nc3ccc(F)cn3)c3ncccc23)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 1/20 0.42
TGFBR1 P36897 1/20 0.38
TGFBR2 P37173 1/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
USP2 O75604 1/20 0.38
GCK P35557 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
PIK3CA P42336 2/20 0.37
EGFR P00533 1/20 0.37
KDR P35968 1/20 0.37
RPS6KA3 P51812 1/20 0.36
KDM1A O60341 1/20 0.36
DGAT2 Q96PD7 1/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ABL1 P00519 1/20 0.35
PABPC1 P11940 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3378893 0.82 CKS1B (0.42) TDO2LMNAMKNK1MKNK2
SCHEMBL3378849 0.82 ABCG2 (0.42) DGAT2
SCHEMBL3378927 0.80 MKNK1 (0.41) MKNK1MKNK2
SCHEMBL3379905 0.78 GRM4 (0.44) TGFBR1TGFBR2KMT2AMEN1USP2
SCHEMBL3379162 0.78 GRM4 (0.41) MKNK1MKNK2
SCHEMBL13070251 0.75 MKNK1 (0.40) TGFBR1PIK3CAMTORMKNK1MKNK2
SCHEMBL3381171 0.72 SLC22A12 (0.37) KMT2AMEN1MKNK1MKNK2
SCHEMBL3379604 0.72 GRM5 (0.39) TDO2LMNAABL1CYP2A6
SCHEMBL3380156 0.71 CKS1B (0.47) KMT2AMEN1KDRNPC1RAB9A
SCHEMBL3379635 0.69 GRM4 (0.39) KMT2APIK3CAKDRNPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1934216-B1 NAPHTHYRIDIN DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-11-24 EP disclosed
EP-1934216-B1 NAPHTHYRIDIN DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-11-24 EP disclosed
US-7511055-B2 Naphthyridin derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-31 US disclosed
US-7511055-B2 Naphthyridin derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-31 US disclosed
US-7511055-B2 Naphthyridin derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-31 US disclosed
EP-1934216-A1 NAPHTHYRIDIN DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-06-25 EP disclosed
WO-2007039512-A1 NAPHTHYRIDIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-12 WO disclosed
WO-2007039512-A1 NAPHTHYRIDIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-12 WO disclosed
US-20070078155-A1 Naphthyridin derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-04-05 US disclosed
US-20070078155-A1 Naphthyridin derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-04-05 US disclosed
US-20070078155-A1 Naphthyridin derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078155-A1 Naphthyridin derivatives GRM5, GRM3, GRM1 TDO2 3820/4885TGFBR1 828/4885TGFBR2 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.